Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer

Abstract Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g. HER2-enriched disease) are more immunog...

Cijeli opis

Bibliografski detalji

Glavni autori:	Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, Valentina Guarneri, Aleix Prat
Format:	Artigo
Jezik:	Inglês
Izdano:	BMJ Publishing Group 2019-03-01
Serija:	Journal for ImmunoTherapy of Cancer
Teme:	Breast cancer HER2 Targeted treatment Immunity Tumor infiltrating lymphocytes Immune checkpoints
Online pristup:	http://link.springer.com/article/10.1186/s40425-019-0548-6
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!